Spectrum Concept of Neuroleptic Malignant Syndrome

Case report: A I5-year-old girl was admitted to our unit in
an excited,apparentlypsychoticstate,diagnosedinitiallyas hypomania. She was treated initially with chlorpromazine, which failed to control her. Haloperidol was substituted, and she made a rapid recovery and was discharged without medication. After a short while, the original symptoms re emerged and she was immediately recommenced on halo peridol as an out-patient. About 5 days later she was referred for admission, with a history of dysphagia, oral thrush, and withdrawal. On this occasion she was drowsy and mute. There was marked â€˜¿ lead pipe' muscular rigidity, but a tremor accompanied any attempted voluntary move ment. She appeared flushed, but had only a mild pyrexia of 37.5CC.Blood pressure was normal, but the pulse rate was raised, both fluctuating significantly during initial obser vation. Non-response to intramuscular procyclidine raised our suspicion of NMS. All medication was discontinued, and she was transferred for in-patient medical care. The girl recovered without active treatment within ten days. Investi gations revealed no leucocytosis or other abnormality, although serum creatine phosphotinase (CPK) was not assessed.
Days after this recovery, a relapse of the original illness occurred and was successfully treated with a brief course of ECT. So far the patient has remained well on lithium.
We made the diagnosis of NMS satisfying the suggested criteria of Kellam (1987) : muscular rigid ity, altered consciousness, and â€˜¿ vegetative dysfunc tion', including pyrexia of @ 37.5Â°C, changes in pulse, blood pressure, etc. However, this case, in common with two of the three cases described by Dr Adityanjee's group, fails to meet their suggested minimum requirements for the diagnosis, which include a pyrexia of @ 39Â°C plus at least two of the following: tachycardia, rapid respirations, blood pressure fluctuations, excessive sweating, and urin ary incontinence. Nevertheless, Dr Adityanjee et al refer to many other reports of idiosyncratic reactions to neuroleptics which comprise some, if not all, of the above criteria. Clearly, neuroleptic drugs are capable of producing a variety of unwanted effects, the â€˜¿ pure' syndrome being by no means always the rule. In addition, NMS is clinically indistinguishable from lethal catatonia, described in psychosis, and from malignant hyperthermia, seen in response to some anaesthetic agents, and is not specific to the use of neuroleptic drugs (Kellam, 1987; Abbott & Loizou, 1986) .
I accept Dr Adityanjee et al's argument for clini cally separating NMS from the commonly encoun tered extrapyramidal side-effects because of the important implications for treatment, but I do not believe that this is a justification for adopting a narrow concept of NMS, as they suggest. I doubt the validity of regarding NMS as a distinct clinical entity, and suggest that all that is required is that clinicians are aware that the signs which comprise the syndrome can occur, so that early detection will lead to discontinuation of the drug and initiation of ap propriate treatment with, hopefully, the avoidance of fatality. 
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